Joshua Hill, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses infectious complications in patients receiving CAR T-cell therapy. In the first month after CAR T-cell therapy, most infections are bacterial, and the biggest risk factor appears to be severe cytokine release syndrome (CRS). At later time points, the incidence of infections decreases, and patients predominantly have respiratory virus infections. Furthermore, Dr Hill outlines infection prevention strategies such as vaccination and administration of IVIG supplementation. This interview took place during the 3rd European CAR T-cell Meeting.
